Clostridioides difficile

Precision Microbiome Therapeutics: Faecalibacterium prausnitzii EXL01 for Prevention of Multiple-Recurrent Clostridioides difficile Infection

By MedXY 09/21/2026

Faecalibacterium prausnitzii EXL01, a single commensal bacterial strain, shows promise in preventing multiple-recurrent CDI by restoring key microbiome functions, including bile acid metabolism and butyrate production, with safety and efficacy comparable to fecal microbiota transplantation.

Gastroenterology news Pediatrics

Probiotics Cut Clostridioides difficile Risk in Antibiotic-Exposed Patients — Small Benefit, Low Certainty

By MedXY 12/18/2025

A 2025 Cochrane update finds probiotics may halve the relative risk of C. difficile-associated diarrhea in antibiotic-treated patients (ARR 1.6%, NNT 65) but evidence is low certainty and applicability varies with baseline risk.

Critical Care Gastroenterology Specialties

Antibiotic Exposure as a Major Risk Factor for Clostridioides difficile Infection: Evidence from a Large Israeli Cohort and Systematic Reviews

By MedXY 08/21/2025

Recent research confirms that antibiotic exposure doubles the risk of hospital-onset Clostridioides difficile infection (CDI), especially in non-carriers, underscoring the central role of antibiotic stewardship and the need for additional preventive strategies in asymptomatic carriers.

Clinical Updates Infectious Diseases news Specialties

Fecal Microbiota Transplantation versus Vancomycin in Primary Clostridioides difficile Infection: A Noninferiority Randomized Trial

By MedXY 07/31/2025

FMT is noninferior to vancomycin for primary CDI, with similar cure rates and safety, suggesting it may be a viable first-line therapy.